Gene expression dynamics of immune mediators in chronic myeloid leukemia patients treated with imatinib

TOLOZA MJ; BESTACH, Y.; LINCANGO YUPANKI M; CAMACHO RODRIGUEZ, M.; BORDONE J; MARIANO R; TARQUI M; PEREZ M; NEGRI ARANGUREN P; ENRICO A; LARRIPA I; BELLI C

Congreso; Reunión conjunta LXVI SAIC, SAI, AAFE, Nanomed Ar.; 2021

Sociedad Argentina de Investigacion Clinica

Imatinib was the first inhibitor approved for chronic myeloid leukemia(CML). Besides its direct oncokinase inhibition, the induction of animmune antitumor mechanism has also been suggested.The aim was to describe the gene expression dynamics of IL2, CIITA,TBET, GATA3, RORGT, FOXP3 and EOMES in CML at diagnosisand during the first year of treatment.Total RNA from peripheral blood samples was collected from 79 CMLpatients (34 serially followed) at diagnosis (n:23) or under treatmentat 3 (n:41), 6 (n42) or 12 (n:26) months classified according to themolecular response at each time. Gene expression was evaluatedby quantitative real-time PCR applying the comparative method 2-ΔCTrelative to GAPDH gene. Statistical analyses were performed usingthe InfoStat software v2019 and p-values